Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

Disclosure in accordance with Belgian Law of 2 May 2007

30 Jan 2018

Press release - Regulated Information

Disclosure in accordance with Belgian Law of 2 May 2007 – Transparency Law

Leuven, Belgium – Pursuant to article 15 of the Belgian Law of 2 May 2007 regarding the publication of major holdings. ThromboGenics NV (Euronext Brussel: THR) publishes the following information:

Status as of 5 January 2018:

 

Total capital:  € 172,201,966.73
Total number of securities conferring voting rights: 38,271,575 shares
Total number of voting rights (denominator):  38,271,575 (one vote per share) 

 

Reason of change 

Capital increase on 5 January 2018, creation of new 2,177,226 shares fully subscribed by Novartis Pharma AG (‘Novartis’).

Additional Information

Capital increase was approved by the extra ordinary shareholder meeting of 20 November 2017.
This information is also available on the ThromboGenics website under ‘Shareholder information’ at (http://www.thrombogenics.com/investors/shareholder-info)

Thresholds set by the Articles of Association

According to the ThromboGenics Articles of Association the applications of Articles 6 to 17 of the Law of 2 May 2007 apply to the legal thresholds of 3 %; 5% and each multiple of 5%.

Notifications

All notifications should be transmitted to both ThromboGenics nv and the FSMA. FSMA recommends transmitting notifications electronically to the email address trp.fin@fmsa.be. It is recommended to forward notifications to ThromboGenics nv electronically as well, directed to the ThromboGenics nv Company Secretary claude.sander@thrombogenics.com.

 

Press release attachment: 
Tags: 
Investors